Ibogaine for Opioid Addiction: What the Evidence Shows

This is the reason almost everybody arrives at this subject, and it is the place where two claims are most often merged into one. Every other indication, from cocaine to nicotine to gambling, is covered on ibogaine for other addictions, where the evidence thins fast and then stops.

The claim splits in two, and the halves are not equal

Claim one. Ibogaine suppresses opioid withdrawal, quickly, after a single administration.

Claim two. People who go through that then stop using opioids.

The first is supported. The second is much weaker, and nearly every account that reaches a general reader presents them as a single finding. Keeping them apart is the only way to read this literature honestly.

What the withdrawal studies measured

The useful thing about this part of the evidence is that different groups used the same instrument, the Subjective Opioid Withdrawal Scale, so the results can be set beside each other.

Thirty people with opioid dependence were followed prospectively in Mexico. Withdrawal scores fell from 31.0 before treatment to 14.0 at roughly three days afterwards. That is more than half, and the authors report it at p < 0.001.

Fourteen people treated legally in New Zealand showed significant reductions on the same scale immediately after treatment.

A series of 191 people detoxifying under inpatient medical monitoring reported diminished withdrawal symptoms and reduced craving.

Three groups, three countries, one direction of effect. For a field where almost nothing replicates, that is worth stating plainly, and this page is not going to talk it away.

Then the effect on drug use fades

The same Mexican cohort is the one that shows what happens next, and it is the most useful single result on this page.

At one month, fifteen people reported no opioid use in the previous thirty days. The paper gives that as 50 per cent, though only twenty of the thirty were actually reached at that point, which is exactly the sort of denominator why there is no success rate is about. Scores for drug use, and for legal and family status, improved against baseline at every follow-up point out to twelve months.

But the improvement in drug use was greatest at one month, and from three months to twelve it settled at a level the authors state did not reach equivalence with that one-month effect.

Why there is no success rate sets out what happened in the larger follow-up cohorts, where roughly seven in ten had relapsed at some point.

The one randomised trial tested a different molecule

This is checkable in a minute and it changes how the rest should be read.

The only randomised, double-blind, placebo-controlled study ever run in opioid-dependent people tested noribogaine, the metabolite, not ibogaine. Twenty-seven patients on methadone maintenance, switched to morphine beforehand, received a single ascending dose or placebo.

So the design everyone would want has been applied once, to a different compound. Every result in the section above comes from observational work with no control group, where the people treated had chosen and usually paid to be there.

What the trials found covers the registry in full, including the 116-person trial that completed in January 2024 and has never reported.

The death in a study of fourteen

The New Zealand study is the most carefully followed cohort in this literature, and it records something that belongs on this page rather than in a footnote.

One participant died during treatment. In a study of fourteen people.

That single sentence carries more information about the risk than any summary statistic, and it sits inside the paper most often cited to show that the benefits last. What ibogaine does to the heart sets out the mechanism, which is well understood and is the reason this is not a treatment anyone should undertake outside medical supervision.

Who wrote which study

The site applies this everywhere and it applies here.

The 191-person series was written by a first author who founded a company holding, by our own count of the register, the largest single patent position in this field. That does not make the observations wrong, and the paper is open access so anyone can read the methods. It does mean the largest series in the literature was produced by an interested party. The iboga patent record sets out the queries.

The New Zealand study includes a co-author salaried by a psychedelic research organisation. It is disclosed on the paper.

What the reviews conclude

Two independent syntheses have appeared recently and they say the same thing.

A 2025 systematic review of psychedelics for opioid use disorder found few completed studies, most of them of weak design and focused on withdrawal, few double-blind or placebo-controlled, and most at high risk of bias from lack of randomisation and blinding.

A 2026 scoping review traces the field’s move away from ibogaine as a single-dose answer towards sequential models, which is itself a comment on how the single-dose claim has held up.

What a reader should take from this

Withdrawal suppression is real, replicated across three countries, and the strongest thing anyone can say about ibogaine.

Detoxification is not treatment. It is the first few days of one, and the follow-up data show what happens when nothing follows it. Aftercare covers the period the studies say matters most and the literature measures least.

Set against what the treatment can do to a heart and against a maintenance treatment that has decades of trial evidence, that is the whole basis on which a decision would be made.